Vartumab ADC-MMAE

**Vartumab ADC-MMAE** is a preclinical, site-specifically conjugated antibody-drug conjugate developed for solid tumors. It consists of the anti-oncofetal chondroitin sulfate single-chain antibody fragment Vartumab, fused to an albumin-binding domain for half-life extension, conjugated through a maleimidocaproyl valine-citrulline para-aminobenzyl carbamate linker to the microtubule-disrupting payload monomethyl auristatin E. Vartumab binds oncofetal chondroitin sulfate on tumor cells, tumor extracellular matrix, and cancer-associated fibroblasts. Following protease-mediated linker cleavage in the tumor microenvironment, released MMAE inhibits tubulin polymerization and can produce membrane-permeable bystander killing. The ADC demonstrated tumor localization and complete tumor regression in melanoma and non-small cell lung cancer xenograft models, with repeat-dose tolerability in rats.

Other names

Vartumab ADC-MMAEVartumab vc-MMAE